Pyrazinamide Market Reaches USD 7.53 Billion in 2026, Driven by Rising Tuberculosis Burden and Expanding Global TB Treatment Programs

Increasing Tuberculosis Control Initiatives and Expanding Access to First-Line Anti-Tuberculosis Therapies to Drive Pyrazinamide Market to USD 17.23 Billion by 2033 at 10.9% CAGR – Coherent Market Insights

Global Pyrazinamide Market, by Patient Type (Adult and Pediatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), is estimated to be valued at US$ 7.53 Bn in 2026 and is expected to exhibit a CAGR of 10.9% during the forecast period (2026-2033), as highlighted in a new report published by Coherent Market Insights.

Browse 28 Market Data Tables and 25 Figures spread through 149 Pages and in-depth TOC on Global Pyrazinamide Market, by Patient Type (Adult and Pediatric), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), - Forecast to 2033"

To know the latest trends and insights related to Global Pyrazinamide Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/pyrazinamide-market-4317

Moreover, according to the WHO, South-East Asia (SEA) region is home to 26% of the world’s population with 44% burden of TB incidence. As per same data source, in 2019, an estimated 4.3 million people suffered from TB and it is estimated that 632,000 died because of TB disease.

Key News

• In 2026, researchers from Maharaja Ranjit Singh Punjab Technical University presented the development of pediatric pyrazinamide tablets using fused deposition modelling 3D-printing technology. The approach is designed to produce customized tablets with patient-specific doses, potentially improving dose accuracy and treatment adherence among children with tuberculosis. The technology could also support flexible tablet sizes, controlled drug release, and decentralized production of age-appropriate anti-tuberculosis medicines.
• In November 2025, TB Alliance announced promising Phase 2 clinical trial results demonstrating that the investigational SPaL regimen, comprising sorfequiline, pretomanid, and linezolid, showed greater anti-tuberculosis activity than the standard HRZE regimen, which includes pyrazinamide. The findings suggest the potential to significantly shorten treatment duration for drug-sensitive tuberculosis while maintaining a comparable safety profile. TB Alliance also plans to advance the regimen into Phase 3 evaluation and explore long-acting injectable formulations. (Source: TB Alliance)

Key Takeaways of the Global Pyrazinamide Market

• The global pyrazinamide market is expected to exhibit a CAGR of 10.9% during the forecast period (2026-2033), owing to increasing product approval and product launches
• Among patient type, adult segment is expected to hold major revenue share in 2033, owing to high burden of TB disease in adult patients.
• Major players operating in the global pyrazinamide market include Pure Chemistry Scientific, LGM Pharma, TCI, HBCChem, Alfa Chemistry, Toronto Research Chemicals, Acros Organics, AlliChem, Waterstone Technology, City Chemical, EDQM, J & K SCIENTIFIC, Meryer (Shanghai) Chemical Technology, Energy Chemical, and Beijing Ouhe Technology.